Abstracts
10 June 2009

Alemtuzumab (Campath-1H)

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
182
Views
256
Downloads

Authors

Monoclonal antibodies (MoAb) augment the host anti-tumor response by selectively targeting the malignant cells. MoAb can mediate anti-tumor effects through three major mechanisms including intrinsic cytotoxic activity, antibody-dependent cellular cytotoxicity (ADCC), and activation of complement-dependent cytolysis. Alemtuzumab is a humanized IgG1 MoAb that targets the glycosylated peptide cell surface antigen CD52 that is abundantly expressed (approximately 500,000 molecules/cell) on normal and malignant B- and T-cells, but not on hemat o poietic stem cells. It was approved by the US Food and Drug Administration (FDA) in 2001 for the treatment of refractory B-cell chronic lymphocytic leukemia (B-CLL).

Altmetrics

Downloads

Download data is not yet available.

Citations

Supporting Agencies

How to Cite